Allen Lee Cohn
University of Southern California
151 Papers
1.1K Citations
Allen Lee Cohn is an academic researcher from University of Southern California. The author has contributed to research in topics: Bevacizumab & Medicine. The author has an hindex of 35, co-authored 142 publications.
Chat about Author
Papers
A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors.
Gayle S. Jameson,John T. Hamm,Glen J. Weiss,Carlos Alemany,Stephen P. Anthony,Michele Basche,Ramesh K. Ramanathan,Mitesh J. Borad,Raoul Tibes,Allen Lee Cohn,Ioana Hinshaw,Robert M. Jotte,Lee S. Rosen,Ute Hoch,Michael A Eldon,Robert A. Medve,Katrina Schroeder,Erica White,Daniel D. Von Hoff +18 more
TL;DR: Etirinotecan pegol showed substantial antitumor activity in patients with various solid tumors and a somewhat different safety profile compared with the irinotecans historical profile.
Treatment Patterns and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Initially Treated with FOLFOX–Bevacizumab or FOLFIRI–Bevacizumab: Results From ARIES, a Bevacizumab Observational Cohort Study
Johanna C. Bendell,Tanios Bekaii-Saab,Allen Lee Cohn,Herbert Hurwitz,Mark Kozloff,H. Tezcan,Nancy Roach,Yeung-Chul Mun,S. Fish,E. Dawn Flick,Darshan Dalal,Axel Grothey +11 more
TL;DR: In first-line mCRC patients, the FOLFOX- bevacizumab and FOLFIRI-bevacIZumab regimens were associated with similar treatment patterns and clinical outcomes.
Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.
David R. Fogelman,Antonio Cubillo,Pilar García-Alfonso,Maria Luisa Limon Miron,John Nemunaitis,Daniel Blake Flora,Christophe Borg,Laurent Mineur,Jose María Vieitez,Allen Lee Cohn,Gene Brian Saylors,Albert Assad,Julie Switzky,Li Zhou,Johanna C. Bendell +14 more
TL;DR: This study evaluated the addition of ruxolitinib, a potent JAK1/2 inhibitor, to regorafenib in patients with relapsed/refractory metastatic CRC.
Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study.
Josep Tabernero,Josep Tabernero,Rebecca R. Hozak,Takayuki Yoshino,Allen Lee Cohn,Radka Obermannova,G. Bodoky,Rocio Garcia-Carbonero,Tudor-Eliade Ciuleanu,David Craig Portnoy,Jana Prausová,K. Muro,Robert W. Siegel,Robert J. Konrad,H. Ouyang,Symantha Melemed,David Ferry,F. Nasroulah,E. Van Cutsem +18 more
TL;DR: The RAISE biomarker program identified VEGF-D as a potential predictive biomarker for ramucirumab efficacy in second-line mCRC and identified an assay appropriate for testing in clinical practice is currently ongoing.
Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).
Marwan Fakih,Kanwal Pratap Singh Raghav,David Z. Chang,Johanna C. Bendell,Timothy S. Larson,Allen Lee Cohn,Timothy K. Huyck,David Cosgrove,Joseph A. Fiorillo,Lawrence Garbo,Shruthi Ravimohan,Von Potter,David D'Adamo,Neelesh Sharma,Ying A. Wang,Sabine Coppieters,Matthias Herpers,Carolina Soares Viana de Oliveira,Andrew Scott Paulson +18 more
TL;DR: The once-weekly treatment of pMMR/MSS metastatic CRC with the combination of regorafenib and EMT is indicated to be a viable combination for this setting.